Targeted therapies may improve oncology patient outcomes

Available targeted medicines—solid tumors

Biomarker development is accelerating

Precision oncology helps to improve patient outcomes

Median overall survival

Gene translocations and fusions (e.g., NTRK3)

Gene copy number variations (CNVs) (e.g., HER2)

Insertions and deletions (indels) (e.g., EGFR exon 19)

Single-nucleotide polymorphisms (SNPs) (e.g., BRCA V600E)

Targeted therapies may improve oncology patient outcomes

Non-small cell lung cancer (NSCLC) patients who have received biomarker-driven therapy as the first-line have had even better survival. Adapted from John A et al. Oncologist. 2020 Nov; 25(11):e1743–e1752.

Approximately 73% of medicines in oncology pipelines have associated biomarkers.